Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 3, 2025 • 9:01 AM ET

Date/Time Source News Release
05/27/2025 07:00 AM EDT PR Newswire BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
05/19/2025 07:00 AM EDT PR Newswire BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
05/15/2025 04:05 PM EDT PR Newswire BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
05/15/2025 07:30 AM EDT PR Newswire BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
05/07/2025 06:30 AM EDT PR Newswire BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
05/06/2025 07:00 AM EDT PR Newswire BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
04/29/2025 06:30 AM EDT PR Newswire BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
04/10/2025 07:30 AM EDT PR Newswire BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS
03/31/2025 07:00 AM EDT PR Newswire BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
03/26/2025 08:15 AM EDT PR Newswire BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
Page

Additional News

As of June 3, 2025 • 9:01 AM ET

Date/Time Source News Release
05/19/2025 02:30 PM EDT PRISM News PRISM Mid-Day Movers: Biotech Volatility and Global Health Advances
05/19/2025 11:31 AM EDT PRISM News BrainStorm Cell Therapeutics Cleared by FDA to Launch Phase 3b Trial of NurOwn(R) for ALS
05/19/2025 10:18 AM EDT SeekingAlpha Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans
05/19/2025 10:17 AM EDT SeekingAlpha Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript
05/19/2025 09:50 AM EDT AllPennyStocks.com Micro Cap Bid Up Aggressively On FDA Clearance Announcement
05/19/2025 08:32 AM EDT 24/7 Market News BrainStorm Secures FDA Clearance to Launch Phase 3b Trial of NurOwn for ALS
05/15/2025 04:48 PM EDT SeekingAlpha BrainStorm Cell Therapeutics GAAP EPS of -$0.45 beats by $0.52
05/15/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, May 15th, 2025
05/15/2025 05:30 AM EDT US Earnings Reports Expected earnings - Brainstorm Cell Therapeutics Inc.
05/14/2025 06:48 PM EDT KlickAnalytics BCLI - Historical Price Movements Surrounding Earnings
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.